Carasent ASA

LSE:0H9M Stock Report

Market Cap: NOK 1.4b

Carasent Valuation

Is 0H9M undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0H9M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0H9M (NOK20.6) is trading below our estimate of fair value (NOK37)

Significantly Below Fair Value: 0H9M is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0H9M?

Key metric: As 0H9M is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0H9M. This is calculated by dividing 0H9M's market cap by their current revenue.
What is 0H9M's PS Ratio?
PS Ratio5.3x
SalesNOK 264.80m
Market CapNOK 1.41b

Price to Sales Ratio vs Peers

How does 0H9M's PS Ratio compare to its peers?

The above table shows the PS ratio for 0H9M vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.1x
INS Instem
3.2x11.4%UK£199.6m
OPT Optima Health
1.2x1.7%UK£138.0m
IUG Intelligent Ultrasound Group
4xn/aUK£39.3m
RENX Renalytix
12.1x126.2%UK£22.4m
0H9M Carasent
5.3x18.6%NOK 1.4b

Price-To-Sales vs Peers: 0H9M is good value based on its Price-To-Sales Ratio (5.3x) compared to the peer average (5.8x).

Price to Sales Ratio vs Industry

How does 0H9M's PS Ratio compare vs other companies in the European Healthcare Services Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
0H9M 5.3xIndustry Avg. 2.2xNo. of Companies11PS02.44.87.29.612+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0H9M is expensive based on its Price-To-Sales Ratio (5.3x) compared to the European Healthcare Services industry average (2.2x).

Price to Sales Ratio vs Fair Ratio

What is 0H9M's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0H9M PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0H9M's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0H9M forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNOK 20.60
NOK 26.00
+26.2%
4.2%NOK 27.00NOK 24.50n/a3
Nov ’25NOK 19.85
NOK 26.75
+34.8%
0.9%NOK 27.00NOK 26.50n/a2
Oct ’25n/a
NOK 25.75
0%
2.9%NOK 26.50NOK 25.00n/a2
Sep ’25n/a
NOK 25.75
0%
2.9%NOK 26.50NOK 25.00n/a2
Aug ’25n/a
NOK 25.75
0%
2.9%NOK 26.50NOK 25.00n/a2
Jul ’25n/a
NOK 25.75
0%
2.9%NOK 26.50NOK 25.00n/a2
Jun ’25n/a
NOK 25.75
0%
2.9%NOK 26.50NOK 25.00n/a2
May ’25NOK 14.33
NOK 25.75
+79.7%
2.9%NOK 26.50NOK 25.00n/a2
Apr ’25NOK 11.17
NOK 26.50
+137.2%
5.7%NOK 28.00NOK 25.00n/a2
Mar ’25NOK 11.26
NOK 26.50
+135.4%
5.7%NOK 28.00NOK 25.00n/a2
Feb ’25n/a
NOK 26.50
0%
5.7%NOK 28.00NOK 25.00n/a2
Jan ’25n/a
NOK 26.50
0%
5.7%NOK 28.00NOK 25.00n/a2
Dec ’24NOK 10.60
NOK 26.50
+150.0%
5.7%NOK 28.00NOK 25.00n/a2
Nov ’24NOK 13.32
NOK 29.00
+117.7%
3.4%NOK 30.00NOK 28.00NOK 19.852
May ’24NOK 15.78
NOK 37.00
+134.5%
5.4%NOK 39.00NOK 35.00NOK 14.332
Apr ’24NOK 16.05
NOK 37.00
+130.5%
5.4%NOK 39.00NOK 35.00NOK 11.172
Mar ’24NOK 16.60
NOK 37.00
+122.9%
5.4%NOK 39.00NOK 35.00NOK 11.262
Feb ’24NOK 16.14
NOK 38.00
+135.4%
2.6%NOK 39.00NOK 37.00n/a2
Jan ’24NOK 16.37
NOK 38.00
+132.1%
2.6%NOK 39.00NOK 37.00n/a2
Dec ’23NOK 17.60
NOK 38.00
+115.9%
2.6%NOK 39.00NOK 37.00NOK 10.602
Nov ’23NOK 17.63
NOK 40.50
+129.7%
8.6%NOK 44.00NOK 37.00NOK 13.322

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$403.49

7D

0.4%

1Y

-15.5%

Enovis

US$2.7b

Operates as a medical technology company focus on developing clinically differentiated solutions worldwide.

0I1B

US$48.46

7D

9.7%

1Y

-3.3%

Patterson Companies

US$1.9b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

0KGB

US$21.68

7D

7.0%

1Y

-14.5%